The Advanced Research Projects Agency for Health will issue $240 million in cancer-related awards over the next few weeks, the White House announced at a Cancer Cabinet meeting Sept. 13.
The first 10 drugs selected for price negotiations under Medicare Part D program includes only one oncology drug: ibrutinib (Imbruvica), a tyrosine kinase inhibitor indicated for the treatment of blood cancers, including chronic lymphocytic leukemia and small lymphocytic lymphoma.
The White House has awarded NCI $50 million to establish five centers for cancer control research in persistent poverty areas.
President Biden announced his intent to nominate Monica Bertagnolli to the post of NIH director.
If you saw Monica Bertagnolli dash around at the Orlando convention center at the annual meeting of the American Association for Cancer Research earlier this week, you would not have guessed that these may be her final days in the NCI director’s job.
Cancer death rates will need to drop faster—by an average of 2.7% per year versus the current rate of 2.3% per year—to achieve the Cancer Moonshot goal of a 50% reduction by 2047.
President Joe Biden is requesting a $920 million increase to the NIH budget in fiscal year 2024, a 1.93% boost. Of that amount, $503 million, or nearly 55%, is slated for NCI, keeping funding for the majority of other NIH institutes and centers at FY23 levels.
President Joe Biden mentioned cancer 13 times in his impassioned State of the Union address and placed cancer research at the top of his Unity Agenda—an indication that his administration would continue to prioritize funding for cancer research in fiscal year 2024.
The American Cancer Society has formed two roundtables—focused on breast and cervical malignancies—to eliminate disparities and improve policies and care systems.
The White House and the American Cancer Society will convene leaders in academic oncology and across public and private arenas to address challenges in breast and cervical cancers on Oct. 24 in Washington, D.C.
